All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
Join our
How to sequence BCMA-directed therapies in early relapsed/ refractory multiple myeloma
At the ESH 7th Translational Research Conference:
Multiple Myeloma
with Martin Kaiser, Mohamad Mohty, and Rakesh Popat
Saturday, October 5, 2024 | 09:10-10:10 CEST
Register nowThis independent educational activity is funded by GSK. All content is developed independently by the faculty. The funders are allowed no influence on the content of this activity.
The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
On 11 October 2017, the Scottish Medicines Consortium (SMC) approved the use of daratumumab as a monotherapy, for a subset of Multiple Myeloma (MM) patients who have had three previous lines of therapy. This prior treatment must include a proteasome inhibitor and an immunomodulatory agent (IMiD), and they must have progressed with the disease during their last therapy. This decision is restricted to this indication only and follows guidance from both the SMC and National Institute for Health and Care Excellence (NICE).
Data from two trials conducted by Janssen were reviewed by the committee: a Phase II trial (MMY2002) and a phase I/II dose-escalation study (GEN 501), for which a pooled analysis revealed an overall response of 31%. The cost-benefit analysis also took into account Janssen’s Patient Access Scheme (PAS), which helps to make this an affordable option for hospitals. This will give new hope to patients with Relapsed and Refractory MM in Scotland who fit these criteria, as effective treatment options at this late stage of the disease are limited.
Interestingly, this decision was in contrast to that made by NICE earlier this year, which rejected approval of daratumumab for the same indication on the basis of limited clinical data. It is hoped that NICE may review their decision later this year.
Your opinion matters
Subscribe to get the best content related to multiple myeloma delivered to your inbox